Breast Implant-Associated Cancers

BIA-ALCL (Breast Implant-Associated Anaplastic Large Cell Lymphoma) is a rare T-cell non-Hodgkin lymphoma that develops in the capsule or fluid surrounding a breast implant. It is not breast cancer — it is a cancer of the immune system. BIA-ALCL is CD30-positive and ALK-negative, and is most commonly associated with textured breast implants. First reported in 1997, it typically presents 7–10 years after implantation with symptoms including late-onset seroma (fluid collection), breast swelling, pain, or a capsular mass.

BIA-SCC (Breast Implant-Associated Squamous Cell Carcinoma) is an extremely rare epithelial cancer that develops within the implant capsule. Unlike BIA-ALCL, it is not a lymphoma but a carcinoma — a cancer arising from epithelial cells. As of 2023, approximately 19 cases have been documented in the medical literature. BIA-SCC tends to be more aggressive than BIA-ALCL and is often diagnosed at a later stage. No clear relationship to implant surface type has been established.

Yes. In addition to BIA-ALCL, the FDA has received reports of other lymphomas developing in the tissue around breast implants, including diffuse large B-cell lymphoma and other non-ALCL lymphoma types. BIA-SCC (squamous cell carcinoma) has also been documented. Dr. Robert Whitfield MD has personally diagnosed a case of Epstein-Barr virus positive large B-cell lymphoma confined to the peri-implant capsule — one of only eight such cases documented worldwide at the time. These findings demonstrate that the chronic inflammatory environment around implants can give rise to multiple types of malignancy.

The most common symptom of BIA-ALCL is a late-onset seroma — an unexplained fluid collection around the implant that develops one or more years after implantation. Other symptoms include persistent breast swelling or asymmetry, breast pain, a palpable mass or lump near the implant, and capsular contracture. Any new or unexplained fluid collection around a breast implant, especially one year or more after surgery, should be evaluated by a qualified surgeon with experience in implant-associated conditions.

Diagnosis of BIA-ALCL requires analysis of the fluid or tissue surrounding the implant. The standard diagnostic workup includes fine needle aspiration of seroma fluid, followed by flow cytometry and immunohistochemistry testing for CD30 positivity. Imaging studies (ultrasound, MRI, or CT) may be used to evaluate the extent of disease. A definitive diagnosis requires pathological confirmation. It is critical that the fluid or tissue be sent to a pathologist experienced with this condition, as standard cytology may miss the diagnosis.

The primary treatment for BIA-ALCL is complete surgical removal of the implant and the entire surrounding capsule (total capsulectomy) with negative margins. When diagnosed early and confined to the capsule (Stage I), complete capsulectomy alone is often curative. Advanced-stage disease may require additional treatment including chemotherapy and radiation therapy. This is why Dr. Robert Whitfield MD advocates for complete capsulectomy in all explant procedures — cancers confined to the capsule would be missed with partial or no capsulectomy.

The vast majority of BIA-ALCL cases have been associated with textured breast implants. Risk estimates range from approximately 1:2,207 to 1:86,029 in patients with textured implants, depending on the cohort studied. While rare cases have been reported in patients with smooth implants, the overwhelming association is with textured surfaces. This led the FDA to request a voluntary recall of certain textured implants in 2019. However, it is important to note that BIA-SCC and non-ALCL lymphomas have not shown the same clear surface-type relationship.

Dr. Robert Whitfield MD recommends complete capsulectomy based on both his research and clinical experience. His PCR-tested study of 694 consecutive explant capsules found that 29% contained bacterial contamination undetectable by standard methods. Additionally, his clinical case of Epstein-Barr virus positive large B-cell lymphoma — found confined to the capsule during routine explant surgery — demonstrates that cancers can exist in capsule tissue that would be missed entirely with partial or no capsulectomy. Given the documented risks of biofilm contamination, chronic inflammation, and the potential for malignancy within capsule tissue, complete removal provides the most thorough approach to patient safety.

Yes. On March 26, 2019, Dr. Robert Whitfield MD testified before the FDA General and Plastic Surgery Devices Panel as President-Elect of the Aesthetic Surgery Education and Research Foundation (ASERF). His testimony addressed breast implant safety concerns, including BIA-ALCL and the need for improved surveillance and reporting. This hearing was part of the FDA's comprehensive review that led to updated safety communications and the voluntary recall of certain textured implants.

Fibrin-associated large B-cell lymphoma is a rare subtype of B-cell lymphoma that develops in the setting of chronic inflammation, typically within fibrous capsules or around medical devices. It is characteristically associated with Epstein-Barr virus (EBV) and displays a Type III latency pattern. When found in the peri-implant capsule, it is confined to the capsule tissue and can be cured with complete capsulectomy achieving negative margins — similar to the treatment approach for BIA-ALCL. Dr. Whitfield diagnosed one such case in October 2020 in a patient with 20-year-old McGhan 410 textured implants.